| Literature DB >> 26930486 |
Chanchal Mandal1, Sun Hwa Kim1, Jin Choul Chai1, Seon Mi Oh1, Young Seek Lee1, Kyoung Hwa Jung2, Young Gyu Chai1,3.
Abstract
Fetal alcohol spectrum disorder is a collective term representing fetal abnormalities associated with maternal alcohol consumption. Prenatal alcohol exposure and related anomalies are well characterized, but the molecular mechanism behind this phenomenon is not well characterized. In this present study, our aim is to profile important genes that regulate cellular development during fetal development. Human embryonic carcinoma cells (NCCIT) are cultured to form embryoid bodies and then treated in the presence and absence of ethanol (50 mM). We employed RNA sequencing to profile differentially expressed genes in the ethanol-treated embryoid bodies from NCCIT vs. EB, NCCIT vs. EB+EtOH and EB vs. EB+EtOH data sets. A total of 632, 205 and 517 differentially expressed genes were identified from NCCIT vs. EB, NCCIT vs. EB+EtOH and EB vs. EB+EtOH, respectively. Functional annotation using bioinformatics tools reveal significant enrichment of differential cellular development and developmental disorders. Furthermore, a group of 42, 15 and 35 transcription factor-encoding genes are screened from all of the differentially expressed genes obtained from NCCIT vs. EB, NCCIT vs. EB+EtOH and EB vs. EB+EtOH, respectively. We validated relative gene expression levels of several transcription factors from these lists by quantitative real-time PCR. We hope that our study substantially contributes to the understanding of the molecular mechanism underlying the pathology of alcohol-mediated anomalies and ease further research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26930486 PMCID: PMC4773011 DOI: 10.1371/journal.pone.0149976
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Functional annotation of differential gene expression.
A) Graphical experimental scheme for differentiation/treatment protocol. NCCIT cells were stabilized and subcultured to form EBs. After stabilization, the EBs were treated with or without EtOH for 48 h. The samples were then collected for further analyses. B) Venn diagram representing the overall distribution of all differentially expressed genes. A total of 632, 205 and 517 differentially expressed genes were identified from NCCIT vs. EB, NCCIT vs. EB+EtOH and EB vs. EB+EtOH, respectively. C) Heat map representing all DEGs that found common between NCCIT vs. EB and EB vs. EB+EtOH datasets. Genes with specific expression patterns were clustered into 4 groups–cluster 1, 2, 3 and 4 represent up-up, up-down, down-down and down-up, respectively. Cluster 2 and 4 were listed here. D) Line graph representing relative expression pattern of those gene clusters defined from the transcriptomic profiling. Genes with specific expression patterns were clustered according to their relative expression values.
Top 15 enriched canonical pathways of all differentially expressed genes in the EB vs. EB+EtOH datasets.
| Ingenuity Canonical Pathways | -log ( | Molecules |
|---|---|---|
| Remodeling of epithelial adherens junctions | 4.04E00 | |
| Sertoli cell-sertoli cell junction signaling | 3.37E00 | |
| Germ cell-sertoli cell junction signaling | 3.21E00 | |
| ILK signaling | 2.68E00 | |
| Glioblastoma multiforme signaling | 2.4E00 | |
| Epithelial adherens junction signaling | 2.4E00 | |
| Phagosome maturation | 2.39E00 | |
| Semaphorin signaling in neurons | 2.29E00 | |
| Gap junction signaling | 2.23E00 | |
| Axonal guidance signaling | 1.94E00 | |
| 14-3-3-mediated signaling | 1.91E00 | |
| D-myo-inositol-5-phosphate metabolism | 1.9E00 | |
| RhoA signaling | 1.82E00 | |
| Actin cytoskeleton signaling | 1.75E00 | |
| PI3K signaling in B lymphocytes | 1.72E00 |
Fig 2Functional enrichment analysis of differentially expressed genes.
A). B) and C) represent Pie charts of cellular and molecular functions of the DEGs (top 10 categories; p-values < 0.05) between NCCIT vs. EB, NCCIT vs. EB+EtOH and EB vs. EB+EtOH, respectively. Numbers in the charts represent the relative genes enriched.
Fig 3Activation of the neuronal development process by ethanol.
A) Network for the category “development of neuron” that was adopted from IPA. The relationship is mentioned at the bottom. B) A functional network analysis of the 11 DEGs that were predicted to activate neuronal development. Boxes represent proposed roles in neuronal development in aspect of expression patterns found in EB vs. EB+EtOH data set. C) qRT-PCR analysis for the relative mRNA expression of the 11 genes responsible for the activation of neuronal development. The expression value was normalized to the GAPDH expression level. Values are represented as average mRNA expression ± SEM bars, n = 3 replicates. Asterisks indicate statistically significant changes based on adjusted p-values < 0.05.
List of TFs that were differentially expressed during early development.
| GeneBank accession no. | Gene symbol | Gene description | Log2(Fold change) |
|---|---|---|---|
| NCCIT vs. EB | |||
| NM_018014 | B-cell CLL/lymphoma 11A (zinc finger protein) | 1.46762 | |
| NM_001171166 | Calmodulin binding transcription activator 2 | 1.04657 | |
| NM_021008 | DEAF1 transcription factor | 1.17328 | |
| NM_005524 | Hes family bHLH transcription factor 1 | 1.52674 | |
| NM_001243961 | Major histocompatibility complex, class II, DQ beta 1 | 1.14242 | |
| NM_002166 | Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein | 1.53728 | |
| NM_024337 | Iroquois homeobox 1 | 1.36066 | |
| NM_002228 | JUN proto-oncogene | 1.61828 | |
| NM_001206833 | K(lysine) acetyltransferase 5 | 1.05922 | |
| NM_001281453 | Methyl-CpG binding domain protein 3 | 1.21166 | |
| NM_002449 | Msh homeobox 2 | 1.55794 | |
| NM_175747 | Oligodendrocyte transcription factor 3 | 1.28199 | |
| NM_021128 | Polymerase (RNA) II (DNA directed) polypeptide L, 7.6kDa | 1.69433 | |
| NM_001136139 | Transcription factor 3 | 1.03986 | |
| NM_001242884 | Zinc finger and BTB domain containing 17 | 1.21244 | |
| NM_032792 | Zinc finger and BTB domain containing 45 | 2.10383 | |
| NM_015117 | Zinc finger CCCH-type containing 3 | 1.09623 | |
| NM_001083113 | Zinc finger, CCCH-type with G patch domain | 1.06153 | |
| NM_153608 | Zinc finger protein 114 | 1.03268 | |
| NM_145911 | Zinc finger protein 23 | 1.11284 | |
| NM_001136036 | Zinc finger protein 692 | 1.1641 | |
| NM_030767 | AT-hook transcription factor | -1.34884 | |
| NM_001030287 | Activating transcription factor 3 | -1.11158 | |
| NM_001193646 | Activating transcription factor 5 | -2.18183 | |
| NM_001252296 | CCAAT/enhancer binding protein (C/EBP), gamma | -1.18295 | |
| NM_001139514 | Dachshund family transcription factor 2 | -1.86629 | |
| NM_001195053 | DNA-damage-inducible transcript 3 | -1.72535 | |
| NM_001278208 | DNA meiotic recombinase 1 | -1.95125 | |
| NM_001160045 | GLI family zinc finger 1 | -1.37881 | |
| NM_001546 | Inhibitor of DNA binding 4, dominant negative helix-loop-helix protein | -1.65549 | |
| NM_001130172 | V-Myb avian myeloblastosis viral oncogene homolog | -1.19446 | |
| NM_005761 | Plexin C1 | -1.43667 | |
| NM_018699 | PR domain containing 5 | -1.29921 | |
| NM_001282116 | Regulatory factor X, 3 (influences HLA class II expression) | -1.13987 | |
| NM_001015881 | TSC22 domain family, member 3 | -1.33723 | |
| NM_024620 | Zinc finger protein 329 | -1.33268 | |
| NM_020813 | Zinc finger protein 471 | -1.30429 | |
| NM_001007169 | Zinc finger protein 483 | -1.25458 | |
| NM_001204835 | Zinc finger protein 568 | -1.24492 | |
| NM_001172677 | Zinc finger protein 607 | -1.19447 | |
| NM_001077349 | Zinc finger protein 682 | -1.25533 | |
| NM_001037232 | Zinc finger protein 829 | -1.12351 | |
| NCCIT vs. EB+EtOH | |||
| NM_002460 | Interferon regulatory factor 4 | 1.13354 | |
| NM_002228 | JUN oncogene | 1.85364 | |
| NM_001170703 | Muscle blind-like 3 (Drosophila) | 1.42077 | |
| NM_001024937 | Misshapen-like kinase 1 (zebrafish) | 1.10139 | |
| NM_004529 | Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 3 | 1.0486 | |
| NM_020062 | SLC2A4 regulator | 1.14312 | |
| NM_004176 | Sterol regulatory element binding transcription factor 1 | 1.00315 | |
| NM_003220 | Transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) | 1.34298 | |
| NM_007068 | DMC1 dosage suppressor of mck1 homolog, meiosis-specific homologous recombination (yeast) | -1.02572 | |
| NM_001033082 | V-Myc myelocytomatosis viral oncogene homolog 1, lung carcinoma derived (avian) | -1.18131 | |
| NM_022367 | SEMA domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4A | -1.11894 | |
| NM_001145671 | Sorbin and SH3 domain containing 2 | -2.23762 | |
| NM_001010879 | Zinc finger protein interacting with K protein 1 homolog (mouse) | -1.02557 | |
| NM_182609 | Zinc finger protein 677 | -1.61246 | |
| NM_032805 | Zinc finger and SCAN domain containing 10 | -1.04282 | |
| EB vs. EB+EtOH | |||
| NM_001248002 | Aryl hydrocarbon receptor nuclear translocator-like 2 | 1.04288 | |
| NM_001030287 | Activating transcription factor 3 | 1.17257 | |
| NM_001193646 | Activating transcription factor 5 | 1.92788 | |
| NM_001139514 | Dachshund family transcription factor 2 | 1.37552 | |
| NM_001195053 | DNA-damage-inducible transcript 3 | 1.08653 | |
| NM_001278208 | DNA meiotic recombinase 1 | 1.72917 | |
| NM_001160045 | GLI family zinc finger 1 | 1.03809 | |
| NM_001546 | Inhibitor of DNA binding 4, dominant negative helix-loop-helix protein | 1.34443 | |
| NM_001170701 | Muscleblind-like splicing regulator 3 | 1.65711 | |
| NM_005761 | Plexin C1 | 1.11354 | |
| NM_018699 | PR domain containing 5 | 1.00847 | |
| NM_145715 | Tigger transposable element derived 2 | 1.14213 | |
| NM_001267597 | Zinc finger protein 248 | 1.11911 | |
| NM_024697 | Zinc finger protein 385D | 1.01064 | |
| NM_001077349 | Zinc finger protein 682 | 1.1168 | |
| NM_001171166 | Calmodulin binding transcription activator 2 | -1.55767 | |
| NM_021008 | DEAF1 transcription factor | -1.15032 | |
| NM_001114123 | ELK1, member of ETS oncogene family | -1.00771 | |
| NM_005524 | Hes family bHLH transcription factor 1 | -1.02254 | |
| NM_003865 | HESX homeobox 1 | -1.56485 | |
| NM_001267039 | La ribonucleoprotein domain family, member 7 | -1.06637 | |
| NM_001130101 | Nuclear receptor subfamily 1, group H, member 3 | -1.19987 | |
| NM_001270523 | Orthodenticle homeobox 2 | -1.0476 | |
| NM_019896 | Polymerase (DNA-directed), epsilon 4, accessory subunit | -1.03574 | |
| NM_021128 | Polymerase (RNA) II (DNA directed) polypeptide L, 7.6kDa | -1.26959 | |
| NM_001077497 | Proline rich 3 | -1.15658 | |
| NM_001015051 | Runt-related transcription factor 2 | -6.79717 | |
| NM_001145670 | Sorbin and SH3 domain containing 2 | -1.72074 | |
| NM_001178078 | Signal transducer and activator of transcription 6, interleukin-4 induced | -1.32528 | |
| NM_030935 | TSC22 domain family, member 4 | -1.34099 | |
| NM_001276373 | Upstream transcription factor 1 | -1.06427 | |
| NM_032792 | Zinc finger and BTB domain containing 45 | -1.44569 | |
| NM_015117 | Zinc finger CCCH-type containing 3 | -1.13058 | |
| NM_001145347 | Zinc finger protein 576 | -1.17224 | |
| NM_001282415 | Zinc finger and SCAN domain containing 10 | -1.68229 | |
Fig 4Distribution of all TF-encoding genes that are altered by ethanol.
A) Venn diagram representing the overall distribution of all differentially expressed TF-encoding genes. A total of 42, 15 and 35 differentially expressed genes were identified from NCCIT vs. EB, NCCIT vs. EB+EtOH and EB vs. EB+EtOH, respectively. A total of 2,16 and 4 genes were common between NCCIT vs. EB and NCCIT vs. EB+EtOH, NCCIT vs. EB+EtOH and EB vs. EB+EtOH, and NCCIT vs. EB and EB vs. EB+EtOH, respectively. B), C) and D) represent heat maps of differential TF-encoding gene expressions between NCCIT vs. EB, EB vs. EB+EtOH and NCCIT vs. EB+EtOH, respectively. Gene expression level of each gene in the heat map is scaled and represented as relative expression value. E) Represents heat maps for TF-encoding genes found common between NCCIT vs. EB and EB vs. EB+EtOH. Genes with specific expression patterns were clustered into 4 groups–cluster 1, 2, 3 and 4 represent up-up, up-down, down-down and down-up, respectively. Only up-down and down-up relationships were found enriched. F) Line graph representing relative expression pattern of those TF-encoding gene clusters defined from the transcriptomic profiling. Genes with specific expression patterns were clustered according to their relative expression values. G), H) and I) represent transcription motif analysis of selected 42, 15 and 35 TF-encoded genes, respectively. Significantly enriched top 5 motifs are presented here (p-value < 0.05). The sequence logos are illustrated in the third column of each table.
Fig 5Confirmation of differential gene expression via qRT-PCR analysis.
A) Validation of the relative mRNA expression of the TF-encoding genes that are randomly selected from the listed 35 genes found in EB vs. EB+EtOH dataset. B) Validation of the relative mRNA expression of the TF-encoding genes in different concentrations of ethanol. The expression value was normalized to the GAPDH expression level. Values are represented as average mRNA expression ± SEM bars, n = 3 replicates. Asterisks indicate statistically significant changes based on adjusted p-values < 0.05.